4D Lifetec secures CHF 23.3 Mio in a share and investment deal with Xlife Sciences opening new horizons in using AI and digital health in early cancer detection.
Summary
4D Lifetec secures CHF 23.3 Mio in a share and investment deal with Xlife Sciences opening new horizons in using AI and digital health in early cancer detection. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions.